Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Study to Assess Safety

NCT03645499
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topical TA-102 A, Topical TA-102 B, Topical TA-102 C, Topical TA-102 D, Topical TA-102 E
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Anakinra for Inflammatory Pustular Skin Diseases

NCT01794117
View directory record Official record
Conditions
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

NCT03873415
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar, Deucravacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

NCT01550744
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

NCT00817219
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriene plus betamethasone dipropionate ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Fremont, California • San Diego, California • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis

NCT03880357
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Betamethasone Scalp Suspension 0.064%;0.0005%, Taclonex®, Placebo topical suspension
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 21, 2026, 10:10 PM EDT
Recruiting Phase 4 Interventional

Duobrii in Combination With Biologics

NCT04119102
View directory record Official record
Conditions
Psoriasis
Interventions
Duobrii
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional

Community Based Trial for AMEVIVE®

NCT00168753
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
36
States / cities
Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 21, 2026, 10:10 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

NCT03384745
View directory record Official record
Conditions
Psoriasis
Interventions
M1095 (Sonelokimab), Placebo, Secukinumab
Drug
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
18 Years to 75 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 21, 2026, 10:10 PM EDT
Recruiting No phase listed Observational

The CorEvitas Psoriasis (PSO) Registry

NCT02707341
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2100
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Recruiting Phase 4 Interventional

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473
View directory record Official record
Conditions
Psoriasis
Interventions
Ilumya Injectable Product
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis

NCT00116181
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT04009499
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • San Diego, California • Palm Harbor, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis

NCT02412644
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
apremilast
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRX003 in Healthy Subjects

NCT02458677
View directory record Official record
Conditions
Psoriasis
Interventions
PRX003, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02514577
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Hot Springs, Arkansas • Encinitas, California • Encino, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Assessing Patient Confidence in Biologic Medications

NCT03168347
View directory record Official record
Conditions
Psoriasis
Interventions
Anecdotal Evidence, Research Study Evidence, Anecdotal + Research Study Evidence, No Evidence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

Randomized Study of PH-10 for Psoriasis

NCT01247818
View directory record Official record
Conditions
Psoriasis
Interventions
PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Oceanside, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 21, 2026, 10:10 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

NCT01856647
View directory record Official record
Conditions
Psoriasis, Obesity
Interventions
Adipose tissue biopsy (fat biopsy)
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

NCT04911751
View directory record Official record
Conditions
Psoriatic Plaque
Interventions
KBL697
Drug
Lead sponsor
KoBioLabs
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Photocil (Topical) for the Treatment of Psoriasis Vulgaris

NCT01916629
View directory record Official record
Conditions
Psoriasis
Interventions
Photocil for Psoriasis, Placebo - Sunscreen (SPF 2)
Drug · Other
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

NCT05896527
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DC-806, Placebo
Drug · Other
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Fountain Valley, California • Santa Monica, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 10:10 PM EDT